Par-4 antagonists for use in the treatment or prevention of influenza virus type a infections
AssigneesInstitut National de la Recherche Agronomique, Hospices Civils De Lyon, Universite Claude Bernard Lyon 1
InventorsBeatrice RITEAU, Ba Vuong LE, Bruno LINA
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions (such as pharmaceutical compositions) comprising PAR4 antagonists for treating or preventing influenza virus type A infections, in particular H1N1 infection. PAR4 antagonists may be combined with a PAR2 agonist or a PAR1 antagonist.
Claims10
A method of treating or preventing an influenza virus type A infection in a subject in need thereof, comprising
- administering to said subject a therapeutically effective amount of a Protease-Activated Receptors-4 (PAR-4) antagonist.
Pharmaceutical composition comprising
- (i) at least one PAR-4 antagonist, and
- (ii) at least one Protease-Activated Receptors-2 (PAR-2) agonist or at least one PAR-1 antagonist.
A method of treating or preventing an influenza virus type A infection in a subject in need thereof, comprising
- administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising
- (i) at least one PAR-4 antagonist, and
- (ii) at least one Protease-Activated Receptors-2 (PAR-2) agonist or at least one PAR-1 antagonist.
A method of treating or preventing an influenza virus type A infection in a subject in need thereof, comprising
- administering to said subject a therapeutically effective amount of
- (i) at least one PAR-4 antagonist, and
- (ii) at least one Protease-Activated Receptors-2 (PAR-2) agonist or at least one PAR-1 antagonist.
Dependencies are inferred from the claim text.